$178 Million is the total value of Foresite Capital Management III, LLC's 10 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 28.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AERI | Aerie Pharmaceuticals, Inc. | $56,811,000 | +25.8% | 2,350,477 | 0.0% | 31.84% | +84.6% | |
| IMMU | Sell | Immunomedics, Inc. | $37,030,000 | +42.7% | 1,750,000 | -10.5% | 20.75% | +109.5% |
| MYOK | Buy | Myokardia, Inc. | $23,796,000 | +52.8% | 326,482 | +9.3% | 13.34% | +124.2% |
| EPZM | Sell | Epizyme, Inc. | $16,911,000 | +64.2% | 687,427 | -31.1% | 9.48% | +141.0% |
| BOLD | Sell | Audentes Therapeutics, Inc. | $13,947,000 | +57.5% | 233,067 | -26.1% | 7.82% | +131.1% |
| XLRN | Acceleron Pharma Inc. | $13,516,000 | +34.2% | 254,923 | 0.0% | 7.58% | +97.0% | |
| NTRA | Sell | Natera, Inc. | $7,033,000 | -25.1% | 208,768 | -27.1% | 3.94% | +9.8% |
| REPL | Sell | Replimune Group, Inc. | $4,505,000 | -43.1% | 313,922 | -44.9% | 2.52% | -16.5% |
| CBAY | Sell | CymaBay Therapeutics, Inc. | $2,949,000 | -61.8% | 1,504,710 | -0.2% | 1.65% | -43.9% |
| ASND | Sell | Ascendis Pharma A/Ssponsored adr | $1,937,000 | -90.1% | 13,922 | -93.2% | 1.09% | -85.5% |
| BHVN | Exit | Biohaven Pharmaceutical Holding Company Ltd. | $0 | – | -53,345 | -100.0% | -0.85% | – |
| AIMT | Exit | Aimmune Therapeutics, Inc. | $0 | – | -611,893 | -100.0% | -4.89% | – |
| BPMC | Exit | Blueprint Medicines Corporation | $0 | – | -559,381 | -100.0% | -15.69% | – |
| ALDR | Exit | Alder BioPharmaceuticals, Inc. | $0 | – | -2,393,612 | -100.0% | -17.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 24 | Q3 2021 | 17.6% |
| Acceleron Pharma Inc. | 22 | Q3 2021 | 25.9% |
| CymaBay Therapeutics, Inc. | 20 | Q3 2022 | 17.6% |
| Aerie Pharmaceuticals, Inc. | 18 | Q1 2020 | 33.5% |
| Ascendis Pharma A/S | 17 | Q3 2022 | 47.8% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 27.4% |
| Natera, Inc. | 16 | Q3 2022 | 21.5% |
| Aimmune Therapeutics, Inc. | 16 | Q3 2019 | 8.1% |
| Verona Pharma PLC. | 15 | Q3 2022 | 30.0% |
| WAVE Life Sciences Ltd. | 15 | Q2 2019 | 20.0% |
View Foresite Capital Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 4 | 2021-11-03 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 3 | 2021-02-10 |
View Foresite Capital Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.